CellSource Co., Ltd. (TYO:4880)

Japan flag Japan · Delayed Price · Currency is JPY
391.00
-10.00 (-2.49%)
Apr 17, 2026, 3:30 PM JST
Market Cap7.76B -50.2%
Revenue (ttm)3.72B -18.5%
Net Income89.08M -89.6%
EPS4.50 -89.8%
Shares Out19.85M
PE Ratio86.98
Forward PE76.29
Dividend5.00 (1.28%)
Ex-Dividend DateOct 30, 2025
Volume54,800
Average Volume60,800
Open400.00
Previous Close401.00
Day's Range391.00 - 404.00
52-Week Range360.00 - 750.00
Beta-0.19
RSI48.80
Earnings DateJun 12, 2026

About CellSource

CellSource Co., Ltd. engages in the regenerative medicine-related businesses in Japan. The company provides processing services to extract adipose-derived stem cells from patients’ adipose tissues, and to prepare platelet-rich plasma from patients’ blood; and offers support services for medical facilities providing regenerative medicine therapy. It is also involved in the sale of human stem cell-derived cosmetic ingredients; and Signalift series of anti-aging products, including a serum. The company was incorporated in 2015 and is headquartered... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2015
Employees 148
Stock Exchange Tokyo Stock Exchange
Ticker Symbol 4880
Full Company Profile

Financial Performance

In fiscal year 2025, CellSource's revenue was 3.71 billion, a decrease of -17.73% compared to the previous year's 4.51 billion. Earnings were 10.00 million, a decrease of -98.92%.

Financial Statements